GTx-758
| Clinical data | |
|---|---|
| Other names | Capesaris |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H13F2NO3 |
| Molar mass | 341.314 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
GTx-758 (tentative brand name Capesaris) is a synthetic nonsteroidal estrogen which was under development by GTx, Inc. for the treatment of advanced prostate cancer. As of 2016, it had completed two phase II clinical trials.